RespireRx Pharmaceuticals Inc (fka RSPI)

[gfp927z]

Thinking further about that ADHD trial protocol, if we currently had some data on say 400-500 mg BID, that would reduce some of the uncertainty we're experiencing now over the amount of dosing liberalization we need to get from the FDA. It's doubtful that we'll ever get to dose at 800 mg BID again with CX-717 (though you never know), but we may not have to, since 400-500 mg BID *might* produce decent efficacy. Unfortunately we didn't dose at that level in the Phase 2, so Cortex and potential BP partners remain in the dark on CX-717's effective dosing for ADHD. "For want of a horse, the kingdom was lost.." Well, hopefully not lost, but sometimes destiny can turn on such seemingly small factors.